Currently, venetoclax is the only approved drug by the FDA for the treatment of chronic lymphocytic leukemia (CLL), and it is a selective BCL-2 protein inhibitor. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.